bemcentinib is currently undergoing phase ii clinical trials for non-small-cell lung cancer (nsclc), triple-negative breast cancer (tnbc), acute myeloid leukemia /myelodysplastic syndrome (aml/mds), melanoma and metastatic pancreatic cancer.